Equities researchers at StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
ALIM has been the subject of several other reports. Craig Hallum reduced their price target on Alimera Sciences from $18.00 to $8.00 in a research report on Monday, April 3rd. HC Wainwright reduced their price target on Alimera Sciences from $9.00 to $5.00 in a research report on Friday, May 19th.
Alimera Sciences Stock Performance
Shares of NASDAQ ALIM opened at $2.35 on Wednesday. The stock has a 50 day moving average price of $1.90 and a 200 day moving average price of $2.55. Alimera Sciences has a 52 week low of $1.30 and a 52 week high of $7.92. The stock has a market capitalization of $17.39 million, a PE ratio of -0.96 and a beta of 1.38.
Institutional Trading of Alimera Sciences
Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in shares of Alimera Sciences by 2.3% in the 2nd quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock valued at $698,000 after purchasing an additional 2,900 shares during the last quarter. Millennium Management LLC bought a new position in shares of Alimera Sciences in the 4th quarter valued at $32,000. Susquehanna International Group LLP bought a new position in shares of Alimera Sciences in the 4th quarter valued at $92,000. Finally, Caligan Partners LP bought a new position in shares of Alimera Sciences in the 4th quarter valued at $1,297,000. 24.58% of the stock is owned by institutional investors and hedge funds.
Alimera Sciences Company Profile
Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.